Novartis AG (NYSE:NVS) – Equities researchers at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for shares of Novartis AG in a note issued to investors on Thursday. Jefferies Group analyst J. Holford forecasts that the brokerage will post earnings of $1.20 per share for the quarter. Jefferies Group also issued estimates for Novartis AG’s FY2018 earnings at $6.19 EPS, FY2019 earnings at $6.81 EPS and FY2020 earnings at $7.58 EPS.

Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.05. The firm earned $12.47 billion during the quarter, compared to analyst estimates of $12.33 billion. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. During the same quarter last year, the business earned $1.25 earnings per share.

Earnings History and Estimates for Novartis AG (NYSE:NVS)

NVS has been the subject of several other research reports. Zacks Investment Research raised shares of Novartis AG from a “hold” rating to a “buy” rating and set a $92.00 price target for the company in a research report on Monday, July 11th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis AG in a research report on Tuesday, September 13th. TheStreet raised shares of Novartis AG from a “hold” rating to a “buy” rating in a research report on Friday, June 24th. Chardan Capital reduced their price target on shares of Novartis AG from $95.00 to $92.00 and set a “buy” rating for the company in a research report on Monday. Finally, Bank of America Corp. reaffirmed a “hold” rating on shares of Novartis AG in a research report on Tuesday, July 12th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $91.33.

Shares of Novartis AG (NYSE:NVS) traded down 0.50% during trading on Friday, reaching $76.38. 2,423,474 shares of the company’s stock were exchanged. Novartis AG has a 12 month low of $69.89 and a 12 month high of $95.11. The firm has a market cap of $181.88 billion, a price-to-earnings ratio of 27.27 and a beta of 0.57. The stock has a 50-day moving average price of $79.43 and a 200 day moving average price of $78.94.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Dearborn Partners LLC increased its position in Novartis AG by 3.1% in the second quarter. Dearborn Partners LLC now owns 342,484 shares of the company’s stock valued at $28,258,000 after buying an additional 10,427 shares during the last quarter. Bartlett & Co. LLC increased its position in Novartis AG by 1.2% in the second quarter. Bartlett & Co. LLC now owns 446,714 shares of the company’s stock valued at $36,858,000 after buying an additional 5,270 shares during the last quarter. Compass Capital Management Inc. increased its position in Novartis AG by 15.3% in the second quarter. Compass Capital Management Inc. now owns 247,197 shares of the company’s stock valued at $20,396,000 after buying an additional 32,845 shares during the last quarter. Royal Bank of Canada increased its position in Novartis AG by 1.8% in the first quarter. Royal Bank of Canada now owns 1,070,573 shares of the company’s stock valued at $77,553,000 after buying an additional 18,714 shares during the last quarter. Finally, Woodley Farra Manion Portfolio Management Inc. acquired a new position in Novartis AG during the second quarter valued at $26,632,000. Institutional investors and hedge funds own 9.78% of the company’s stock.

About Novartis AG

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.